Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY4175408 |
| Synonyms | |
| Therapy Description |
LY4175408 is an antibody-drug conjugate (ADC) comprising an Fc-silenced antibody targeting PTK7 conjugated to exatecan, which potentially inhibits growth of PTK7-expressing tumors (Eur J Cancer 211 (2024): 114998). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY4175408 | LY-4175408|LY 4175408 | LY4175408 is an antibody-drug conjugate (ADC) comprising an Fc-silenced antibody targeting PTK7 conjugated to exatecan, which potentially inhibits growth of PTK7-expressing tumors (Eur J Cancer 211 (2024): 114998). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07046923 | Phase I | LY4175408 | A Study of LY4175408 in Participants With Advanced Cancer | Recruiting | USA | FRA | ESP | 2 |